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KEY POINTS SUMMARY: 
 
• Dobutamine stress echocardiography (DSE) is a validated tool for the non-invasive 
evaluation of myocardial ischaemia and makes feasible the recording of heart rate 
variability in non-resting conditions. 
• In this study we determined whether individuals with transient myocardial ischaemia had 
different autonomic responses to the stress of dobutamine infusion compared to non-
ischaemic (normal) responders. 
• Non-ischaemic responders had a residual predominance of parasympathetic over 
sympathetic activity. However, under conditions of myocardial ischaemia, there was a 
directionally opposite cardiac autonomic response with a residual increase of sympathetic 
over parasympathetic modulation. 
• The sympathetic response to dobutamine stress is augmented as the burden of myocardial 
ischaemia is increased. 
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ABSTRACT: Cardiac autonomic dysfunction has prognostic significance in patients with coronary 
artery disease. This investigation aimed to assess changes in autonomic modulation induced by 
dobutamine stress in the presence and absence of myocardial ischaemia. Three hundred and 
fourteen individuals underwent dobutamine stress echocardiography to detect or exclude 
myocardial ischaemia. Simultaneous autonomic and haemodynamic data were obtained using a 
plethysmographic device. Total power spectral density and associated low frequency (LF) and 
high frequency (HF) power spectral components in absolute (ms2) and normalised units (nu) 
were determined. Participants were categorised as non-ischaemic (NI) or ischaemic (IS) 
responders. There were no significant differences in LFnu or HFnu between groups at baseline. 
At peak stress, LFnu decreased from baseline in NI (43±1.8 to 40±1.8%), but increased from 
baseline in IS responders (39.5±2 to 56±2%, p<0.05). In contrast, HFnu increased in NI patients 
(57±1.8 to 60±1.8%) but decreased in IS responders (60.5±2 to 44±2%, p<0.05). Those with a 
high ischaemic burden (>3 ischaemic left ventricular [LV] segments) had a greater increase in 
LFnu (41±4.8 to 65±3.2% vs 44.8±3.8 to 57.7±3.1%, p<0.05) and greater decrease in HFnu 
(59±4.8 to 35±3.2% vs 55.2±3.8 to 42.3±3.1%, p<0.05) compared to patients with a low 
ischaemic burden (1-3 ischaemic LV segments) respectively, at peak stress. In the absence of 
myocardial ischaemia, dobutamine stress is associated with a residual predominance of 
parasympathetic over sympathetic activity. Under conditions of ischaemia, there is a 
directionally opposite autonomic response with a significant residual increase of sympathetic 
over parasympathetic modulation. This response is augmented as the burden of ischaemia is 
increased. 
 
 
 4 
ABBREVIATIONS: ANS, autonomic nervous system; BRS, baroreceptor reflex sensitivity; BSA, 
body surface area; BP, blood pressure; CAD, coronary artery disease; dBP, diastolic blood 
pressure; DSE, dobutamine stress echocardiography; E, early transmitral filling veloctiy; Ea, 
early transmitral tissue Doppler velocity; HF, high frequency; HR, heart rate; HRV, heart rate 
variability; IS, ischaemic; LF, low frequency; LV, left ventricle; LVEF, left ventricular ejection 
fraction; NI, non-ischaemic; NU, normalised unit; PSD, power spectral density; sBP, systolic 
blood pressure; TFM, task force monitor; Vp, flow propagation velocity; WMSI, wall motion 
score index. 
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INTRODUCTION             
 
The autonomic nervous system (ANS) modulates depolarization of the sino-atrial node, inducing 
cyclical variations in R-R intervals. Heart rate variability (HRV), a marker of neural outflow 
modulation, is a valuable non-invasive tool for examining autonomic cardiovascular control 
(Floras, 2009). High-frequency (HF) oscillation (0.15 to 0.4 Hz) of R-R intervals is regarded as a 
marker of parasympathetic modulation and, although contentious, low-frequency (LF) oscillation 
(0.04 to 0.15 Hz) of R-R intervals is considered a marker of cardiac sympathetic activity 
(Akselrod et al., 1981; Malliani et al., 1991). 
 
A reduced HRV predicts morbidity and mortality in healthy populations (Tsuji et al., 1994; 
Dekker et al., 1997) and in patients with coronary artery disease (CAD) (Hayano et al., 1990; 
van Boven et al., 1998). These studies have been conducted under resting conditions. There are 
few data on changes in autonomic modulation during functional myocardial stress in humans. 
Small sample size observational studies have indicated that during myocardial ischaemia there is 
an increase in LF oscillations of HRV (Yoshio et al., 1993; Binkley et al., 1995; Lanza et al., 
1996; Joho et al., 1999) and LF/HF ratio (Petrucci et al., 1996; Manfrini et al., 2004), suggesting 
a predominance of sympathetic activity. However, the results are inconclusive due to significant 
differences in the nature of the stressor and haemodynamic workloads between patient groups. 
Petrucci et al. (1996) analysed differences in autonomic function between myocardial ischaemic 
and non-ischaemic patients, in response to microcirculatory vasodilator challenge with 
dipyridamole. Binkley et al. (1995) used dobutamine infusion to test for differences in autonomic 
function between ischaemic and non-ischaemic patients. Within this study, ischaemic responders 
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had a significantly higher heart rate response (haemodynamic workload) compared to non-
ischaemic patients. It is therefore unclear if the reported differences in autonomic modulation are 
due to myocardial ischaemia. Research in canine models demonstrated that the ANS plays an 
important role in modulating the cardiovascular effects of dobutamine, buffering the 
chronotropic and pressor responses via reductions in systemic vascular resistance (Liang & 
Hood, 1979).   
 
We present a large observational study, the aim of which was to assess the cardiac autonomic 
response to myocardial stress and to determine whether differences exist in ischaemic and non-
ischaemic responders at comparable external, haemodynamic and myocardial workloads. We 
postulated that any differences may, in part, provide another mechanism for increased 
myocardial vulnerability during ischaemia.  
 
Dobutamine stress echocardiography (DSE) was the model we selected, as it is a functional test 
validated for the diagnosis of CAD and it can differentiate low and high-risk patients according 
to the presence or absence of myocardial ischaemia (Sicari et al., 2003).  
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METHODS 
 
Ethical Approval  
 
All procedures for this investigation conformed to Declaration of Helsinki principles and the 
National Research Ethics Service Committee for London-Harrow approved the study 
(09/H0710/37). Signed informed written consent was obtained from all participants.  
 
Study Design and Patients 
 
We prospectively recruited 314 patients undergoing clinically indicated DSE for the evaluation 
of angina pectoris. All patients underwent DSE with simultaneous autonomic and haemodynamic 
monitoring. Exclusion criteria included unstable angina, severe aortic stenosis, age <18 years, 
inability to consent, patients not in sinus rhythm and a left ventricular ejection fraction (LVEF) 
<40% (due to the confounding influence impaired LV function has on measures of HRV). In 
addition, patients who developed extra-systoles and those who required atropine to achieve target 
HR were excluded. The DSE results were interpreted by 2 or more experienced readers (>5 years 
experience), who were blinded to the results of all other tests. 
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Echocardiographic Image Acquisition 
 
All image acquisitions and measurements were performed as recommended by the American 
Society of Echocardiography (Schiller et al., 1989). LVEF was determined by the modified 
biplane Simpson’s rule, with measurements averaged over three cardiac cycles. Pulsed Doppler 
was used to record transmitral flow in the apical four-chamber view. Flow propagation velocity 
(Vp) was calculated from colour M mode in the apical four chamber view. Tissue Doppler 
velocities were acquired at the lateral mitral annulus. LV filling pressure was estimated from the 
mitral E/Ea and E/Vp ratios (Ommen et al., 2000). Measured values were indexed to body 
surface area (BSA). 
 
Dobutamine Stress Challenge 
 
Patients underwent a standard DSE protocol (Pellikka et al., 1995) with stepwise infusion of 
dobutamine in 3-minute stages of 10, 20, 30, 40 µg⋅kg-1⋅min-1. β-blocker therapy was stopped 
72-hours before DSE. Images were acquired in standard parasternal long- and short-axis and 
apical two, three, and four chamber views at baseline, during infusion of dobutamine and in 
recovery. Baseline, low-dose (HR 10–15 beats above baseline), peak, and recovery (10-minutes 
after infusion terminated) images were stored in digital quad screen format for off-line analysis. 
A 12-lead electrocardiogram (ECG) and blood pressure (BP) were recorded at each infusion 
stage. Criteria for terminating the test were achievement of target HR of (220–age) x 0.85 b⋅min-
1, development or deterioration of wall motion abnormalities, angina, ST depression >2 mm, 
systolic blood pressure (sBP) increase to >240 mmHg or decrease to <100 mmHg, diastolic 
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blood pressure (dBP) increase >140 mmHg, and if severe ventricular or supraventricular 
arrhythmias developed. The LV was divided into a 17-segment model for qualitative analysis 
(Cerqueira et al., 2002). Regional myocardial wall motion was described as normal, 
hyperkinetic, hypokinetic, akinetic, or dyskinetic. In the non-ischaemic (normal) response, a 
segment is normokinetic or hypokinetic at rest with an overall increase in wall motion during 
stress. In the ischaemic response, a segment worsens its function during stress from 
normokinesis to hypokinesis, akinesis, or dyskinesis (Armstrong, 1991). Based on the 
myocardial response to dobutamine during stress echocardiography, patients were categorised as 
non-ischaemic or ischaemic. The resting and peak wall motion score index (WMSI) was 
calculated. Patients were further categorised with low (1-3 ischaemic LV segments) or high (>3 
ischaemic LV segments) ischaemic burden as per European Society of Cardiology guidelines 
(Sicari et al., 2008). For patients with poor endocardial border definition in 2 or more contiguous 
LV segments, the intravenous LV contrast agent SonoVue® was used to ensure optimal LV 
border definition. 
 
Autonomic and Haemodynamic Assessment 
 
The Task Force® Monitor (TFM) (CNSystems, Graz, Austria) is a validated non-invasive 
monitoring system (Fortin et al., 2001), which was used for the continuous beat-to-beat 
monitoring and real-time calculation of all autonomic and haemodynamic parameters. HR was 
calculated from the ECG, beat-to-beat stroke index by impedance cardiography (Fortin et al., 
2006a), and beat-to-beat BP by the vascular unloading technique (Fortin et al., 2006b). Beat-to-
beat BP was automatically corrected to oscillometric BP values obtained from the brachial artery 
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of the contralateral arm. Baroreceptor reflex sensitivity (BRS) was automatically calculated 
using the sequence method (Bertinieri et al., 1985), which is based on computer identification of 
a series of successive increases or decreases in sBP (3 beats) and assessment of the effect on 
pulse interval. The slope of the regression line between the sBP and pulse interval in each 
sequence is taken as an index of the BRS control of the heart (Di Rienzo et al., 2001; Valipour et 
al., 2005). Total peripheral vascular resistance was calculated according to Ohm’s law and 
indexed to BSA.  
 
HRV was calculated using power spectral analysis and applying an autoregressive model (Fortin, 
1998). Specific frequencies within the power spectrum of HRV have been previously used to 
quantify autonomic nervous control of the cardiovascular system. LF-HRV is considered a 
marker of sympathetic efferent drive to the heart (Akselrod et al., 1981; Pomeranz et al., 1985; 
Montano et al., 1994) and HF-HRV is an indicator of parasympathetic cardiac modulation 
(Akselrod et al., 1981; Pomeranz et al., 1985). Parameters of HRV were automatically calculated 
by the TFM and expressed in absolute (ms2) and normalised units (nu). The normalisation of the 
frequency components of HRV has proven crucial to the interpretation of data (Malliani et al., 
1994) and the ratio of LF-to-HF for HRV is an accepted index of cardiac sympathovagal balance 
(Ditor et al., 2005). 
 
Heart Rate Variability Data Analysis 
 
The TFM records HRV data continuously and intervention marks enable the separation of the 
cumulative HRV data into independent stages during DSE. Intervention marks were set at 
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baseline, at each incremental dose of dobutamine infusion (10, 20, 30, and 40 µg⋅kg-1⋅min-1), and 
at 3 and 10-minutes into recovery. Fifteen minutes of supine resting HRV data was obtained, in 
line with current short-term HRV recording recommendations (Marek et al., 1996). During DSE, 
the intervention marks allowed independent HRV sampling for each 3-minute incremental dose 
of dobutamine as well as sampling at 3 and 10-minutes into recovery. All biological signals were 
recorded with a sample frequency of 1000 Hz and 16-bit resolution. 
 
Statistics 
 
Unless otherwise stated, continuous variables were expressed as mean±SD. All data were 
analysed using the statistical package for social sciences (SPSS 19 release version for Windows; 
SPSS Inc., Chicago IL, USA). Differences between and within groups were determined by 2-
way repeated measures ANOVA and Chi-square test was used to compare categorical data. The 
C statistic (area under the receiver operator curve [AUC]) was computed as a measure of the 
ability for HRV to discriminate non-ischaemic and ischaemic patients. A p value <0.05 was 
regarded as statistically significant. 
 
 
 
 
 
 
 
 12 
RESULTS 
 
General 
 
Of the 379 patients referred for DSE, 65 were excluded from our final analyses (Figure 1). Table 
1 shows the demographic characteristics. The DSE examination result was interpreted as positive 
for inducible myocardial ischaemia in 62 (19.7%) patients and negative in 252 (80.3%). There 
were no significant differences between non-ischaemic (NI) and ischaemic (IS) patients with 
respect to age, sex, BSA, smoking history, hypertension, hypercholesterolemia, diabetes, 
previous percutaneous coronary intervention, previous myocardial infarction, left ventricular 
hypertrophy and anti-ischaemic drugs (Table 1). Family history of cardiovascular disease was 
more common in IS responders (p<0.001). In addition, IS responders were more likely to have 
undergone coronary artery bypass graft surgery and be on aspirin (all p<0.05).  
 
When IS patients were further evaluated (Table 2), patients with greater LV ischaemic burden 
(>3 ischaemic LV segments) were older and more likely to be on aspirin compared to patients 
with low ischaemic burden (1-3 ischaemic LV segments) (all p<0.05).  
 
Dobutamine stress response and echocardiographic classification 
 
No adverse events occurred during the DSE procedure and the dobutamine dose was comparable 
between groups (32.4±6 and 34.9±4 µg⋅kg-1⋅min-1, IS and NI group respectively). Significant 
differences (all p<0.05) were seen between IS and NI patient groups with LV end systolic 
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diameter, LV end diastolic diameter, LVEF, WMSI, mitral E/Ea, and mitral E/Vp at baseline and 
peak dose dobutamine (Table 3). LV maximal wall thickness was similar in the 2 groups.  
 
Haemodynamic response to dobutamine stress 
 
Table 4 shows the haemodynamic response to dobutamine stress in IS and NI responders. At 
baseline, only dBP differed between groups. In NI responder’s dobutamine stress produced a 
significant increase in HR (p<0.001), sBP (p<0.05), rate pressure product (p<0.001), and cardiac 
index (defined as cardiac output/body surface area) (p<0.05), and a significant decrease in stroke 
index (p<0.05), and total peripheral resistance index (p<0.001). In IS responder’s dobutamine 
stress produced a significant increase in HR (p<0.001), rate pressure product (p<0.001), and 
cardiac index (p<0.05), and a significant decrease in stroke index (p<0.05), and total peripheral 
resistance index (p<0.001). At peak dose dobutamine significant differences between IS and NI 
responders were seen in sBP, dBP, and cardiac index (all p<0.05).  
 
Autonomic response to dobutamine stress 
 
Autonomic responses to dobutamine stress in IS and NI patients are shown in figure 2 and table 
4. Dobutamine infusion produced a significant reduction in R-R power spectral density (PSD) 
and associated R-RLFms2 and R-RHFms2 oscillations in both IS and NI responders from 
baseline to peak dose dobutamine (all p<0.001). At baseline, IS patients had significantly lower 
PSD and R-RLFms2 (both p<0.05) compared to NI patients. At peak dose dobutamine IS patients 
had significantly lower R-RLFms2 and R-RHFms2 (both p<0.05) compared to NI patients. When 
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analyzing HRV in normalised units (nu), R-RHFnu (44±2% vs 60±1.8%) and R-RLFnu (56±2% 
vs 40±1.8%) differed significantly (all p<0.05) between IS and NI responders respectively, at 
peak dose dobutamine. From baseline to peak dose dobutamine R-RHFnu tended to increase 
(57±1.8% to 60±1.8%) in NI responders, but significantly decreased (p<0.05) in IS responders 
(60.5±2% to 44±2%). In contrast, from baseline to peak dose dobutamine R-RLFnu tended to 
decrease (43±1.8% to 40±1.8%) in NI responders, but significantly increased (p<0.05) in IS 
responders (39.5±2% to 56±2%). From baseline to peak dose dobutamine, the R-RLF/HF ratio 
tended to increase in IS responders (1.32±0.12 to 1.7±0.09) and tended to decrease in NI 
responders (1.6±0.21 to 1.3±0.09). There was a significant group by time interaction for R-
RLFnu and R-RHFnu (F (4,26) = 4.33, p<0.05) and the LF/HF ratio (F (4,18) = 3.65, p<0.05). 
 
Of note, there were no significant differences in BRS between groups during dobutamine 
infusion and no significant differences were seen in autonomic function according to ischaemic 
territory (anterior versus posterior myocardial ischaemic regions). Furthermore, baseline total 
power spectral density of HRV was a poor indicator of the development of myocardial ischaemia 
during DSE (AUC = 0.56, 95% CI 0.48 – 0.64, p=0.17). 
 
Ischaemic Burden 
 
When IS responders were further evaluated, patients with greater ischaemic burden (>3 
ischaemic LV segments) had a significantly higher pulse pressure, and significantly lower R-
RPSD and R-RLFms2 (all p<0.05) compared to low ischaemic burden (1-3 ischaemic LV 
segments) patients at baseline (Table 5). Patients with the greatest ischaemic burden 
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demonstrated a significantly greater increase in R-RLFnu oscillations (41±4.8 to 65±3.2% vs 
44±3.8 to 57.7±3.1%, p<0.05) and greater decrease in R-RHFnu (59±4.8 to 35±3.2% vs 55.2±3.8 
to 42.3±3.1%, p<0.05) compared to patients with low ischaemic burden, from baseline to peak 
dose dobutamine. Significant differences between ischaemic groups were also seen in recovery 
(Figure 3).   
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DISCUSSION 
 
Our study has shown that autonomic modulation during dobutamine infusion is significantly 
different between IS and NI responders at comparable external, haemodynamic and myocardial 
workloads. In the absence of myocardial ischaemia, dobutamine stress is associated with a 
residual predominance of parasympathetic over sympathetic activity. Vagal activation promotes 
vasodilatation (Kovach et al., 1995) and may exert anti-fibrillatory effects (Myers et al., 1974; 
La Rovere et al., 2002). In contrast, under conditions of ischaemia, there is a reverse alteration of 
autonomic balance with greater residual sympathetic over parasympathetic activity.  
 
Patients with highest ischaemic burden (>3 ischaemic LV segments) demonstrated a significantly 
greater move towards a residual predominance of sympathetic over parasympathetic activity 
compared to patients with low ischaemic burden (1-3 ischaemic LV segments). This suggests 
that the shift in residual autonomic balance is related to the magnitude of the ischaemic response. 
Importantly, significant differences were also seen at rest in PSD and absolute measures of R-
RLFms2 between IS and NI groups and between those with high versus low ischaemic burden. A 
low HRV is associated with increased risk of death and a reduced LF has been associated with 
greater sympathetic activity in high-risk cardiac patients (Kotecha et al., 2011). 
 
Comparison with previous studies 
There are few studies that have assessed autonomic function during myocardial ischaemia and all 
had small sample sizes. Lanza et al. (1996) and Yoshio et al. (1993) analysed changes in HRV 
during episodes of spontanteous ST segment elevation detected on Holter monitor. However, it is 
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difficult to ascertain if all ST segment changes were due to ischaemia. Joho et al. (1999) used 
balloon coronary occlusion, which is non-physiological with the potential for infarction as well 
as ischaemia. Manfrini et al. (2004) compared balloon inflation with spontaneous ischaemia but 
the mean duration of HRV analysis was more than double for spontaneous ischaemia, which 
would influence HRV data. Petrucci et al. (1996) assessed changes in HRV in IS and NI patients 
during dipyridamole infusion; however IS patients had lower doses of the drug than NI, which 
may have caused the differences reported. In addition, dipyridamole itself has direct effects on 
sympathetic outflow from the central nervous system (Lucarini et al., 1992). Binkley et al. 
(1995) used dobutamine stress to ascertain differences in HRV response in 16-patients. However 
IS patients had a significantly greater haemodynamic response, which may, in part, have 
accounted for the results. In addition, ischaemic burden, BRS, and recovery were not assessed. 
 
Possible explanations for the autonomic responses 
Several possible mechanisms could be suggested to explain the autonomic responses that we 
found, but most are problematic. (a) Haemodynamic workload cannot be the cause of the 
differences, since there were no significant differences with respect to HR or BRS from baseline 
to peak dose dobutamine. (b) Altered reflexes associated with LV hypertrophy are unlikely to 
account for our findings since LV wall thickness was similar in those with and without 
ischaemia. (c) Dobutamine dose was comparable between groups; and (d) the medications of the 
two groups of patients were comparable. (e) The autonomic dysfunction known to be associated 
with impaired systolic function does not fully explain our data since mean LVEF was within 
normal limits in both IS and NI groups; and (f) similarly, although differences in diastolic 
function existed between IS and NI groups, there was no significant difference in diastolic 
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function between patients with low vs high ischaemic burden (data not shown). This would 
suggest diastolic function contributes to the observed difference between IS and NI groups, but 
cannot be the sole cause. (g) The absence of differences in BRS is a significant negative result 
bearing in mind the known reduction in BRS in some post-MI patients who have an associated 
increased arrhythmic risk. However, in the best known of these studies, that of La Rovere et al. 
(1998), the increased risk in post-MI patients was significant only when HRV and BRS (<3.0 
ms·mmHg-1) were depressed and risk was greatest in patients with a LVEF <35%. In patients 
with a BRS >6.1 ms·mmHg-1 there was a 2-year mortality rate of just 2%. At baseline in our 
study, mean BRS was ≥11 ms·mmHg-1 for NI, IS, and low and high ischaemic burden patients. 
In addition, no significant differences in autonomic modulation were seen in our IS patients 
according to ischaemic territory. This contrasts with typical clinical findings in post-MI patients 
with anterior versus posterior infarction, in whom differences in the reflex response to 
myocardial injury are observed according to anatomical region of injury, characteristically with 
posterior MI resulting in bradycardia and hypotension (Bezold-Jarisch effect) and anterior MI 
more frequently evoking tachycardia and hypertension (Bainbridge reflex) (Webb et al., 1972; 
Zipes, 1990). The differences observed in our study may be due to our subjects experiencing 
transient ischaemia compared to myocyte injury tissue necrosis. 
 
We recognise that IS patients had a significantly lower LVEF and significantly higher estimated 
LV filling pressure than NI responders. These differences may have contributed to the observed 
differing autonomic responses of the 2 groups during stress. This may also be true for the greater 
number of patients in the IS group who underwent previous coronary intervention. In addition, 
although not significantly different, IS patients and those with a higher ischaemic response had a 
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higher percentage of patients with diabetes. It is well known that pre-clinical cardiomyopathy is 
associated with cardiac autonomic neuropathy in patients with diabetes and as well as being at 
higher risk of presenting with myocardial ischaemia, these patients also have a higher prevalence 
of autonomic neuropathy (Dinh et al., 2011). However, although these differences likely impact 
cardiac autonomic modulation between the two groups, myocardial ischaemia also appears to 
play a significant role. This is particularly evident when IS patients were divided according to the 
degree of myocardial ischaemia. We found that a dose-response relationship exists, such that 
patients with greater myocardial ischaemia demonstrate a greater increase in residual 
sympathetic over parasympathetic modulation compared to low ischaemic burden patients.  
 
In NI responders, the Bezold-Jarisch reflex (Mark, 1983) may explain the autonomic response 
seen. Stimulation of inhibitory cardiac receptors by stretch (mechanoreceptor stimulation) and 
chemoreceptor stimulation due to acidosis and reactive oxygen species (Huang et al., 1995; 
Longhurst et al., 2001) augments parasympathetic modulation and inhibits sympathetic activity, 
governed by vagal reflexes. In the IS group, this response may have been delayed, potentially 
due to diminished sympathoinhibitory reflexes. Myocardial ischaemia is capable of producing 
transient dysfunction of autonomic cardiac modulation, which can extend into the reperfusion 
period (Malliani et al., 1969; Abe et al., 1997). Indeed, loss of vagal reflex has been shown with 
coronary occlusion (Zipes, 1990). A cardiac sympathetic reflex response may be activated by 
metabolic mediators (Malliani et al., 1983; Longhurst et al., 2001), such as adenosine, which 
may affect neurotransmission in the ischaemic area and acts as a biochemical stimulus in the 
ischaemic cascade. This functional neural impairment may have important clinical implications, 
since it may contribute to ventricular tachyarrhythmias (Abe et al., 1997). Dysfunction of 
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sympathoinhibitory reflexes has been demonstrated through a reduction in sBP, reduced 
inotropy, and through altered ventricular dilation (Floras, 1993). Indeed, IS patients had 
significantly greater LV dilatation and a significantly reduced CI, sBP, and LVEF at peak dose 
dobutamine, which supports this concept.  
 
The coronary circulation is dynamic, responding to changes in metabolic tissue demand via 
arterial vasodilatation and vasoconstriction and therefore controlling blood flow and oxygen 
delivery to the myocardium. Neural and endocrine stimuli including cardiac adrenergic signals 
are important mediators in regulating myocardial blood flow (Di Carli et al., 1997). An increase 
in sympathetic nerve activity causes coronary artery dilatation and thus increases myocardial 
blood flow (Zeiher et al., 1989), and atherosclerosis is associated with an impairment in the 
capability of the coronary arteries to dilate (Zeiher & Drexler, 1991; Zeiher et al., 1991). In 
addition, ischaemia and the metabolic process itself may directly promote an increase in 
sympathetic nerve activity as described above. 
 
Patient follow-up was too short to derive any prognostic significant of the autonomic response 
seen. However, a reduced HRV and sympathetic activation is associated with CAD, 
hypertension, heart failure and a poorer prognosis (Marek et al., 1996). Indeed, a recent 
angiographic study demonstrated a high inverse correlation with LF power and severity of CAD 
(Kotecha et al., 2011). Furthermore, sympathetic drive and parasympathetic withdrawal reflected 
by changes in HRV has been demonstrated in ambulatory human subjects with ischaemic 
episodes (Bernardi et al., 1988) and before the onset of major arrhythmic events in patients with 
implantable cardioverter defibrillators (Guzzetti et al., 2005). Therefore, the results of this study 
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may have many clinical implications for patients with ischemic heart disease and explain, in part, 
a potential cause of increased mortality seen in this group.  
 
To our knowledge this is the first human functional myocardial stress study to compare 
differences in autonomic modulation between IS and NI responders at comparable external, 
haemodynamic and myocardial workloads as well as evaluating differences in the magnitude of 
ischaemia. The findings are consistent with results of previous research, however, a potential 
association of this response with the generation of arrhythmia and increased mortality, requires 
further research. 
 
Clinical Perspective 
Cardiac autonomic dysfunction, specifically a decrease in parasympathetic activity and the 
presence of myocardial ischaemia are associated with an increased risk of mortality. It may be 
suggested that patients who exhibit such responses are candidates for closer surveillance, which 
may include early revascularization and/or more aggressive pharmacological and/or device 
therapy to protect against premature mortality.    
 
Study Limitations 
The interplay between the ANS and myocardial ischaemia are complex and difficult to study in 
humans. In this study we used DSE since it is a reproducible, standardized, non-invasive clinical 
technique used to analyze transient myocardial ischemia. In addition, it enables stationary 
recording, which is essential for HRV recording. However, although DSE has high sensitivity 
and specificity, it is operator dependent and subjective in detection of inducible myocardial 
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ischemia. In order to reduce subjectivity two experienced independent observers reported images 
off line.  
 
It may not be possible to differentiate endogenous autonomic modulation from direct myocardial 
stimulation from dobutamine on HRV. However, persistent beta stimulation produced by a 
steady-state infusion of dobutamine may not itself be expected to directly alter the dynamic 
phasic changes associated with HRV (Binkley et al., 1995). Therefore, the differences observed 
in HRV are probably induced by reflexive autonomic modulation in response to the changes in 
chemical and mechanical milieu of the myocardium during dobutamine administration.  
 
We recognise that sampling HRV data for only 3-minutes at each stage of dobutamine infusion is 
a limitation. However, we felt it would have been inappropriate to modify a routine standardised 
clinical investigation in order to obtain longer periods of recording at each incremental dose. In 
addition, although non-ischaemic patients within the study cannot be regarded as normal 
subjects, the absence of inducible myocardial ischaemia makes them an appropriate control 
group for the study.  
 
The Bezold-Jarisch reflex might, at least in the case of the NI patients, explain the findings; to 
pursue this, one could conduct a microneurographic study during DSE to look at sympathetic 
efferent activity with greater precision and temporal resolution, but it would not be a very easy or 
tolerable study in practice. A further limitation is that we did not control for respiratory rate at 
rest or during dobutamine infusion. However, metronome-guided respiration is not necessarily 
required for HRV measurement if subjects avoid irregular respiration (Kobayashi, 2009). 
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Furthermore, previous research has demonstrated that dobutamine infusion does not significantly 
alter breathing rate (van de Borne et al., 1999). 
 
CONCLUSION 
 
Our findings suggest that in the absence of myocardial ischaemia, dobutamine stress is 
associated with a significant increase in residual parasympathetic over sympathetic modulation. 
However, during ischaemia, there is a directionally opposite response in residual autonomic tone, 
with greater sympathetic compared to parasympathetic activity. This response is augmented as 
the burden of ischaemia is increased.  
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Figure legends 
 
Figure 1: DSE=dobutamine stress echocardiography. 
 
Figure 2: Autonomic response to dobutamine stress in ischaemic and non-ischaemic patient 
groups (mean [SEM]). Note: A=R-R Power spectral density (HRV) response; B=R-R normalised 
units low frequency response; C=R-R normalised units high frequency response; D=R-R LF/HF 
Ratio; *=p<0.05 between groups; †=p<0.05 and ‡=p<0.001 within groups from baseline to peak 
dose dobutamine; §=p<0.05 and ||=p<0.001 within groups from peak dose dobutamine to 
recovery.   
 
Figure 3: Autonomic response to dobutamine stress in patients with low and high ischaemic 
burden (mean [SEM]). Note: A=R-R Power spectral density (HRV) response; B=R-R normalised 
units low frequency response; C=R-R normalised units high frequency response; D=R-R LF/HF 
Ratio; *=p<0.05 between groups; †=p<0.05 and ‡=p<0.001 within groups from baseline to peak 
dose dobutamine; §=p<0.05 and ||=p<0.001 within groups from peak dose dobutamine to 
recovery.   
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Table 1. Baseline Characteristics of Ischaemic and Non-Ischaemic Patient Groups. 
Characteristics  Non-Ischaemic Ischaemic 
  (n=252) (n=62) 
Demographics    
 Age (yrs) 64±11.2 66.9±11.9 
 Male 128 (50.8%) 36 (58.1%) 
 Height (cm) 174.4±9.9 174.8±8.8 
 Weight (kg) 78.6±18.5 75.2±14.5 
 BSA (m2) 1.85±0.23 1.85±0.18 
History    
 Hypertension 107 (42.5%) 32 (51.6%) 
 Hypercholesterolemia 63 (25%) 21 (33.9%) 
 Diabetic 42 (16.6%) 17 (27.4%) 
 Family Hx of CVD 10 (4%) 14 (22.6%)† 
 Previous PCI 47 (18.7%) 17 (27.4%) 
 Previous CABGS 30 (11.9%) 13 (21%)* 
 Previous MI 16 (6.3%) 7 (11.3) 
 LVH 50 (19.8%) 13 (21%) 
 Current smoker 6 (2.4%) 3 (4.8%) 
 Previous smoker 1 (0.4%) 1 (1.6%) 
Cardiac Medication   
 ACE 107 (42.5%) 22 (35.5%) 
 Angiotensin II receptor antagonist 50 (19.8%) 14 (22.6%) 
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Table 1. Baseline Characteristics of Ischaemic and Non-Ischaemic Patient Groups (cont). 
 Aspirin 162 (64.3%) 53 (85.5%)* 
 Beta blockers 111 (44%) 31 (50%) 
 Calcium antagonists 108 (42.9%) 29 (46.8%) 
 Diuretic 93 (36.9%) 28 (45.2%) 
 Lipid-lowering agents 40 (15.9%) 19 (30.6%) 
 Nitrates 62 (24.6%) 23 (37.1%) 
 Warfarin 16 (6.3%) 3 (4.8%) 
Values are mean±SD, n (%). 
BSA=Body surface area; Family Hx of CVD=Family history of cardiovascular disease; 
PCI=Percutaneous coronary intervention; CABGS=Coronary artery bypass graft surgery; 
MI=Myocardial infarction; LVH=Left ventricular hypertrophy; ACE=Angiotensin converting 
enzyme inhibitor; *=p <0.05; †=p<0.001 between groups. 
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Table 2. Baseline Characteristics of Patients with Low and High Ischaemic Burden. 
Characteristics  Low High 
  (n=44) (n=18) 
Demographics    
 Age (yrs) 64.6±12.9 72.5±8* 
 Male  28 (63.6%) 8 (44.4%) 
 Height (cm) 176.6±9.9 174.5±8.5 
 Weight (kg) 76.2±16.9 74.8±12.3 
 BSA (m2) 1.84±0.21 1.85±0.27 
History    
 Hypertension 24 (54.5%) 8 (44.4%) 
 Hypercholesterolemia 12 (27.3%) 9 (50%) 
 Diabetic 9 (20.5%) 8 (44.4%) 
 Family Hx of CVD 9 (20.5%) 5 (27.8%) 
 Previous PCI 11 (25%) 6 (33.3%) 
 Previous CABGS 8 (18.2%) 5 (27.8%) 
 Previous MI 5 (11.4%) 2 (11.1%) 
 LVH 8 (18.2%) 5 (27.8%) 
 Current smoker 1 (2.3%) 2 (11.1%) 
 Previous smoker 0 (0%) 1 (5.6%) 
Cardiac Medication   
 ACE 14 (31.8%) 8 (44.4%) 
 Angiotensin II receptor antagonist 11 (25%) 3 (16.7%) 
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Table 2. Baseline Characteristics of Patients with Low and High Ischaemic Burden (cont). 
 Aspirin 35 (79.5%) 18 (100%)* 
 Beta blockers 22 (50%) 9 (50%) 
 Calcium antagonists 22 (50%) 7 (38.9%) 
 Diuretic 20 (45.5%) 8 (44.4%) 
 Lipid-lowering agents 11 (25%) 8 (44.4%) 
 Nitrates 15 (34.1%) 8 (44.4%) 
 Warfarin 1 (2.3%) 2 (11.1%) 
Values are mean±SD, n (%). 
BSA=Body surface area; Family Hx of CVD=Family history of cardiovascular disease; 
PCI=Percutaneous coronary intervention; CABGS=Coronary artery bypass graft surgery; 
MI=Myocardial infarction; LVH=Left ventricular hypertrophy; ACE=Angiotensin converting 
enzyme inhibitor; *=p<0.05 between groups. 
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Table 3. Comparison of Echocardiography Results Between Ischaemic and Non-Ischaemic Patient 
Groups. 
Parameter  Non-Ischaemic Ischaemic 
  (n=252) (n=62) 
Baseline    
 LVESD (mm) 32±12 38±16* 
 LVEDD (mm) 64±33 69±22* 
 LVEF (%) 64±17 55±15* 
 WMSI  1.0±0.2 1.2±0.5* 
 Maximal LVEDD Wall Thickness (cm) 1.16±0.32 1.13±0.71 
 LA size (mm) 43±11 45±16 
 E/A ratio  1.29±0.8 1.31±0.5 
 Mitral E Deceleration Time (ms) 214±115 226±103* 
 E/Ea ratio  8±3 12±5* 
 E/Vp ratio 1.36±0.89 1.54±0.63* 
Peak Dose Dobutamine    
 LVESD (mm) 21±12 34±16* 
 LVEDD (mm) 48±26 67±36* 
 LVEF (%) 76±33 62±18* 
 WMSI 1.0±0.1 1.4±0.2* 
 LA size (mm) 44±15 45±18 
 E/A ratio 1.18±0.4 1.22±0.6 
 Mitral E Deceleration Time (ms) 316±153 196±64* 
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Table 3. Comparison of Echocardiography Results Between Ischaemic and Non-Ischaemic Patient 
Groups (cont). 
 E/Ea ratio  11.3±7.6 14.1±8.2* 
 E/Vp ratio 1.56±0.69 1.89±0.84* 
Values are mean±SD.  
LVESD=Left ventricular end systolic diameter; LVEDD=Left ventricular end diastolic diameter; 
LVEF=Left ventricular ejection fraction; WMSI=Wall motion score index; LA=Left atrium; 
E/A=Ratio of peak velocity of early filling to peak velocity of atrial filling; Mitral E/Ea=Ratio of 
transmitral blood flow velocity to tissue Doppler velocity; E/Vp=Ratio of peak velocity of early 
filling to flow propagation velocity; *=p<0.05 between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
